

Pain Therapeutics Conference - Latest updates on developments in targeting nerve growth factors

SMI's 15th annual Pain Therapeutics conference will be taking place on the 18th - 19th May 2015 in London, UK. Book by 27th February to save £300

LONDON, ENGLAND, UNITED KINGDOM, February 12, 2015 /EINPresswire.com/ -- SMI's Pain Therapeutics [conference](#) is a must attend event for attendees who want to benchmark their organisation with recent developments in the [pain therapeutics arena](#) and methods on how to overcome the challenges faced. The conference will examine principles and illustrative case studies on current activities and trends in clinical and pre-clinical evidence-based and best-practice-based pain medicine.

A promotional poster for the SMI's 15th annual Pain Therapeutics Conference. The poster features the SMI logo (SMi LINKING BUSINESS with INFORMATION) at the top right. The main title 'Pain Therapeutics Conference' is in large purple font. Below it, the location 'Holiday Inn Bloomsbury, London, UK' and dates '18th - 19th MAY 2015' are displayed. On the left, there is a graphic of a human torso showing the skeletal structure and muscles, with a yellow and red glow around the shoulder area. At the bottom, the website 'www.pain-therapeutics.co.uk' is listed in white text on a black background.

Benefits of Attending Include:

- New for 2015 - Presentations on personalized medicine for pain, biomarkers and CGRP receptor antagonists for migraine treatment
- Learn about Grunenthal's latest screening approach for neuropathic pain and pain models
- Hear timely case studies from Merck and Afferent Pharmaceuticals
- Spotlight sessions - Latest updates on developments in targeting nerve growth factors
- Discover latest advances in the treatment of pain from leading, pharma, biotech and academic experts from the industry
- Interactive panel discussion the reviewing validity of animal models for chronic pain

KEY SPEAKERS INCLUDE:

- Professor Anthony Jones, Professor of Neuro-Rheumatology, Human Pain Research Group, University of Manchester
- Professor Richard Knowles, CEO, Arachos Pharma
- Dr Emanuele Sher, Senior Research Advisor, Neuroscience, Discovery, Lilly Research Centre, Eli Lilly
- Dr Anthony P. Ford, Chief Scientific Officer, Afferent Pharmaceuticals
- Dr Richard Butt, Senior Director, Research Project Leader, Clinical Research, Pfizer
- Dr Shahnaz Yusaf, Investigator Biopharm Innovation BDU, GlaxoSmithKline
- Dr Ian Bell, Principal Scientist, Discovery Chemistry, Merck
- Dr Mark T. Brown, MD, Executive Director, Clinical Program Leader for Osteoarthritis and Cancer Pain Studies, Pfizer Inc
- Dr Gregor Bahrenberg, Associate Scientific Director, Grunenthal

Pain Therapeutics is sponsored by: CHDR & PRA Health Sciences

[Book](#) by 27th February to save £300

For more information or to register visit <http://www.smi-online.co.uk/2015pain-therapeutics18.asp>

Alternatively, contact Magdalena Georgieva on +44 (0)20 7827 6148 or email mgeorgieva@smi-online.co.uk

----- END -----

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Margaret Mugema
SMi Group Ltd
+44 (0) 20 7827 6072
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/249558626>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

